Core Viewpoint - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. plans to increase its investment in its wholly-owned subsidiary, Jinbo Medical, by 165 million yuan to support strategic development and business needs [1] Group 1: Investment Details - The registered capital of Jinbo Medical will increase from 35 million yuan to 200 million yuan following the capital increase [1] - The funding for this capital increase will come from the company's own funds and loans from new policy-based financial instruments, with no new shareholders involved [1] Group 2: Subsidiary Overview - Jinbo Medical, established on January 31, 2023, is located in Daxing District, Beijing, and its business scope includes the production of cosmetics, sanitary products, disposable medical supplies, and Class III medical devices [1] - As of September 30, 2025, Jinbo Medical's unaudited total assets are approximately 99.08 million yuan, with net assets around 30.60 million yuan [1] Group 3: Project Information - Jinbo Medical is the main entity for implementing the "Humanized Collagen FAST Database and Product Development Platform Project" of Jinbo Biological, which is currently under construction and has not yet generated operating income [1]
锦波生物拟向位于北京市大兴区的生物材料子公司增资1.65亿